Search results for "Intravenou"

showing 10 items of 390 documents

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a …

2007

Abstract Background To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). Patients and methods At total of 190 patients were randomly assigned to receive capecitabine 1000 mg/m2 twice daily on days 1–14 plus oxaliplatin 130 mg/m2 on day 1 (CapOx), capecitabine 825 mg/m2 twice daily on days 1–14 plus gemcitabine 1000 mg/m2 on days 1 and 8 (CapGem) or gemcitabine 1000 mg/m2 on days 1 and 8 plus oxaliplatin 130 mg/m2 on day 8 (mGemOx). Treatment cycles were repeated every three weeks. The primary end point was progression-free survival (PFS) rate at 3 months; secondary end points included objective response rate, carboh…

AdultMalemedicine.medical_specialtyAdolescentMaximum Tolerated DoseOrganoplatinum CompoundsPhases of clinical researchKaplan-Meier EstimateDeoxycytidineRisk AssessmentGastroenterologyDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind MethodProgression-free survivalInfusions IntravenousCapecitabineAgedNeoplasm StagingProbabilityDose-Response Relationship Drugbusiness.industryCAPOX RegimenHematologyMiddle AgedImmunohistochemistrySurvival AnalysisGemcitabineGemcitabineOxaliplatinSurgeryOxaliplatinPancreatic NeoplasmsRegimenTreatment OutcomeOncologyTolerabilityFemaleFluorouracilbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Treatment of human brucellosis with rifampin plus minocycline

2003

In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocyc…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMinocyclineRisk AssessmentDrug Administration SchedulePharmacotherapyRecurrenceInternal medicinemedicineHumansPharmacology (medical)ChildInfusions IntravenousAdverse effectAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologyChemotherapyDose-Response Relationship Drugbusiness.industryRetrospective cohort studyMinocyclineMiddle AgedBrucellaSurgeryTreatment OutcomeInfectious DiseasesItalyOncologyTolerabilityChild PreschoolbrucellosisDrug Therapy CombinationFemaleRifampinbusinessRifampicinFollow-Up Studiesmedicine.drug
researchProduct

The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients

1990

In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compar…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPhagocytosisImmunologyCellAutoimmune DiseasesRandom AllocationAntigenInternal medicinemedicineHumansInsulinImmunology and AllergyChildAutoantibodiesGlycemicAutoimmune diseaseC-Peptidebiologybusiness.industryInsulinImmunization PassiveReceptors Interleukin-2medicine.diseaseDiabetes Mellitus Type 1medicine.anatomical_structureEndocrinologyIntravenous ImmunoglobulinsChild Preschoolbiology.proteinFemaleAntibodybusinessJournal of Autoimmunity
researchProduct

Preoperative Anxiety and Its Influence on Patient and Surgeon Satisfaction in Patients Receiving Dental Implant Surgeries Performed Under Intravenous…

2017

Purpose: The aims of this study were to evaluate the relationship of age, sex, and type and duration of the surgery with preoperative anxiety in patients undergoing dental implant surgeries under intravenous conscious sedation, and to assess preoperative anxiety association with the postoperative satisfaction of both the patient and surgeon. Materials and Methods: This prospective study included 180 patients receiving dental implant surgeries under intravenous conscious sedation by means of midazolam, fentanyl, and propofol. Preoperative anxiety (Corah Dental Anxiety Scale), number of implants, duration of surgery, surgeon satisfaction (evaluated as three categories: patient too awake and n…

AdultMalemedicine.medical_specialtyAnesthesia DentalMidazolamSedationConscious SedationFentanyl03 medical and health sciences0302 clinical medicinePatient satisfactionDental AnxietymedicineHumansHypnotics and SedativesProspective StudiesProspective cohort studyPropofolAgedDental Implantsbusiness.industry030206 dentistryGeneral MedicineMiddle AgedSurgeryFentanylDental ImplantationIntravenous anesthesiaPatient Satisfaction030220 oncology & carcinogenesisAnesthesiaAnesthesia IntravenousMidazolamAnxietyFemaleOral Surgerymedicine.symptomPropofolbusinessAnesthetics Intravenousmedicine.drugThe International Journal of Oral & Maxillofacial Implants
researchProduct

Intra- and extracerebral blood flow changes and flushing after intravenous injection of human corticotropin-releasing hormone

1994

To study facial flush after systemic administration of human corticotropin-releasing hormone (hCRH) we injected 100 micrograms hCRH intravenously to ten healthy young men. The increase in facial temperature was measured by infrared camera. A significant increase in facial temperature of 1.39 degrees C +/- 0.3 was found within 7 min in all patients, which lasted up to 60 min, although facial flushing was visible in only 50% (5/10) of the probands. In a second experiment 100 micrograms hCRH was then administered to seven other healthy young men. Intra- and extracerebral blood flow velocity changes in the medial cerebral artery (MCA) and external carotid artery (ECA) were measured after hCRH a…

AdultMalemedicine.medical_specialtyCorticotropin-Releasing HormoneExternal carotid arteryCerebral arteriesHemodynamicsVasodilationmedicine.arteryInternal medicineDrug DiscoveryHyperventilationFlushingmedicineHumansHyperventilationGenetics (clinical)business.industryGeneral MedicineBlood flowVasodilationEndocrinologyCerebrovascular CirculationFaceAnesthesiaCarotid Artery ExternalInjections IntravenousMiddle cerebral arteryCirculatory systemMolecular MedicineEndothelium Vascularmedicine.symptomSkin TemperaturebusinessThe Clinical Investigator
researchProduct

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

2007

In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the relapse rate and progression of disability. In patients with chronic progressive MS, a beneficial effect of IVIG was not documented in placebo controlled studies. This trial investigated the influence of IVIG in primary (PPMS) and secondary (SPMS) chronic progressive MS. Two-hundred and thirty-one patients stratified for PPMS ( n = 34) and SPMS ( n = 197) were randomly assigned to IVIG 0.4 g/kg per month or to placebo for 24 months. Primary endpoints were 1) the time to sustained progression of disease identified as worsening of the expanded disability status scale (EDSS) sustained for 3 months, and …

AdultMalemedicine.medical_specialtyDiseasePlaceboPlacebosCentral nervous system diseaseDisability EvaluationDegenerative diseaseQuality of lifeRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProspective StudiesDepression (differential diagnoses)AgedExpanded Disability Status Scalebusiness.industryMultiple sclerosisImmunoglobulins IntravenousMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseSurgeryTreatment OutcomeNeurologyDisease ProgressionFemaleNeurology (clinical)businessMultiple Sclerosis Journal
researchProduct

Investigation into isoprenaline resistance in patients with obstructive lung disease

1974

12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.

AdultMalemedicine.medical_specialtyDrug ResistanceDrug resistancePlaceboPlacebosElectrocardiographyHeart RateIsoprenalineInternal medicineHeart ratemedicineHumansPlethysmographInfusions ParenteralPharmacology (medical)Lung Diseases ObstructiveAgedPlethysmography Whole BodyAsthmaPharmacologyAnalysis of VarianceClinical Trials as Topicbusiness.industryAirway ResistanceIsoproterenolGeneral MedicineMiddle Agedmedicine.diseaseStimulation ChemicalObstructive lung diseaseAirway ObstructionBronchodilatationAnesthesiaInjections IntravenousCardiologyFemalebusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon.

1998

Objectives: α-Interferons (α-IFN) have been shown to be effective in the treatment of chronic viral C hepatitis, but their efficacy remains unsatisfactory. Recently natural β-interferon (β-IFN) administered by intravenous infusion has been used successfully. Methods: To evaluate the efficacy and safety of intravenous β-IFN administration we treated 20 patients with histologically proven chronic hepatitis C who were nonresponders to at least two previous courses of α-IFN treatment. All patients received 6 million units (MU) of natural human fibroblast β-IFN by drip infusion, 6 times per wk for 8 wk and were followed up for 6 months after suspension of treatment. Results: Five patients (25%) …

AdultMalemedicine.medical_specialtyGenotypeHepacivirusHepatitis C virusmedicine.medical_treatmentAlpha interferonHepacivirusmedicine.disease_causeGastroenterologyInternal medicinemedicineHumansInfusions IntravenousInterferon alfaHepatitisbiologyHepatologybusiness.industryGastroenterologyInterferon-alphaImmunotherapyInterferon-betaHepatitis C Chronicbiology.organism_classificationmedicine.diseaseSurgeryTreatment OutcomeRNA ViralFemaleViral diseasebusinessViral loadmedicine.drugThe American journal of gastroenterology
researchProduct

Left ventricular volume determination using Albunex.

1996

The aim of this study was to assess the ability of intravenous injection of Albunex to improve left ventricular volume determination in patients with various cardiac diseases. It is conceivable that the intravenous injection of microbubbles could improve echocardiographic left ventricular border delineation leading to improved interobserver variability. Echocardiograms were obtained during simultaneous intravenous injection of 0.08 and 0.12 ml/kg Albunex (four-chamber view). Within 6 hours after the recording of the contrast echocardiograms routine left heart angiography was performed. Volumes were measured using the slice method in native and contrast echocardiograms as well as in the angi…

AdultMalemedicine.medical_specialtyHeart DiseasesSystoleCardiac VolumeHeart angiographyContrast MediaEnd systoleVentricular Function LeftDiastoleInternal medicineAlbuminsmedicineConfidence IntervalsHumansRadiology Nuclear Medicine and imagingIn patientEnd diastoleAgedObserver VariationEjection fractionbusiness.industryCineradiographyAngiocardiographyHeartStroke VolumeMiddle AgedConfidence intervalMicrospheresEchocardiographyInjections IntravenousCardiologyMicrobubblesVentricular volumeFemaleCardiology and Cardiovascular MedicinebusinessJournal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
researchProduct

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct